Brexpiprazole: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland) and PBAC (Australia) recommended or restricted brexpiprazole, while AWMSG (Wales) did not recommend it.
On the same population the two systems disagree outright: PBAC (Australia) recorded recommended for “Schizophrenia”, while AWMSG (Wales) recorded not recommended for “Treatment of schizophrenia in adult patients.”.
Assessment has run over 6.6 years, from 19 Dec 2018 at AWMSG (Wales) to 2025 at PBAC (Australia).
CIPM (Spain) changed its position: not recommended on 17 Jun 2020, recommended by 19 Jun 2025, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), SMC (Scotland) and PHARMAC (New Zealand) among them — hold no record for brexpiprazole at all.
The file is active: 4 of 7 records date from 2023 or later.
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess brexpiprazole, on 19 Dec 2018; PBAC (Australia) did not open a file until 2025 — a wide spread of 6.6 years between the earliest and latest system to look at it.
CIPM (Spain) is the only agency to have returned to brexpiprazole, recording 3 separate entries.
Coverage is narrow: only 5 of the 18 agencies here have assessed brexpiprazole.
The full ledger for brexpiprazole reads 3 recommended, 2 not recommended, 1 restricted and 1 advice.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Schizophrenia | Recommended | source |
| AOTMIT (Poland) | 13 Sep 2023 | Rxulti reimbursement recommendation | recommended conditionally | source |
| CIPM (Spain) | 17 Jun 2020 | SECRETARIA GENERAL DE SANIDAD MINISTERIO SANIDAD MINISTERIO DE SANIDAD Indicación terapéutica: Tratamiento de la esquizo… | not financed by the SNS (financed 2023-12) | source |
| ZIN (Netherlands) | 16 Apr 2019 | GVS-advies brexpiprazol (Rxulti®) voor de behandeling van schizofrenie bij volwassenen | advice published (GVS) | source |
| AWMSG (Wales) | 19 Dec 2018 | Treatment of schizophrenia in adult patients. | not endorsed (non-submission) | source |
2 further decisions for brexpiprazole, across 1 agency, are not shown here. They link to 2 further source documents.
Related molecules
- aripiprazole — same ATC class N05A — Psycholeptics
- risperidone — same ATC class N05A — Psycholeptics
- paliperidone — same ATC class N05A — Psycholeptics
- olanzapine — same ATC class N05A — Psycholeptics
- quetiapine — same ATC class N05A — Psycholeptics
- lurasidone — same ATC class N05A — Psycholeptics
Coverage: 7 decisions for brexpiprazole from 5 agencies, 2018 to 2025. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.